Literature DB >> 19943049

BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML).

Carlos Santamaría1, María C Chillón, Ramón García-Sanz, Cristina Pérez, María D Caballero, María V Mateos, Fernando Ramos, Alfonso García de Coca, José M Alonso, Pilar Giraldo, Teresa Bernal, José A Queizán, Juan N Rodríguez, Noemí Puig, Ana Balanzategui, María E Sarasquete, Miguel Alcoceba, Joaquín Díaz-Mediavilla, Jesús San Miguel, Marcos González.   

Abstract

We have analyzed brain and acute leukemia, cytoplasmic (BAALC) gene expression and other genetic markers (ERG, EVI1, MN1, PRAME, WT1, FLT3, and NPM1 mutations) in 127 intermediate-risk acute myeloid leukemia (AML) patients: 98 cytogenetically normal and 29 with intermediate-risk cytogenetic alterations. High versus low BAALC expressers showed a higher refractoriness to induction treatment (31% vs 10%; p = .005), lower complete remission rate after salvage therapy (82% vs 97%; p = .010), and lower 3-year overall (23% vs 58%, p < .001) and relapse-free survival (26% vs 52%, p = .006). Similar results were found when cytogenetic subgroups were analyzed separately. Multivariate models confirmed the unfavorable prognosis of this marker. In conclusion, BAALC is a relevant prognostic marker in intermediate-risk AML.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19943049     DOI： 10.1007/s00277-009-0864-x

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


  10 in total

1.  Prognostic significance of the BAALC gene expression in adult patients with acute myeloid leukemia: A meta-analysis.

Authors:  Shi-Ji Xiao; Jian-Zhen Shen; Jin-Long Huang; Hai-Ying Fu
Journal:  Mol Clin Oncol       Date:  2015-05-11

2.  BAALC potentiates oncogenic ERK pathway through interactions with MEKK1 and KLF4.

Authors:  K Morita; Y Masamoto; K Kataoka; J Koya; Y Kagoya; H Yashiroda; T Sato; S Murata; M Kurokawa
Journal:  Leukemia       Date:  2015-06-08       Impact factor: 11.528

3.  BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Authors:  Sebastian Schwind; Guido Marcucci; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Kelsi B Holland; Dean Margeson; Heiko Becker; Susan P Whitman; Yue-Zhong Wu; Klaus H Metzeler; Bayard L Powell; Jonathan E Kolitz; Thomas H Carter; Joseph O Moore; Maria R Baer; Andrew J Carroll; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  Blood       Date:  2010-09-14       Impact factor: 22.113

4.  Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia.

Authors:  Ann-Kathrin Eisfeld; Guido Marcucci; Sandya Liyanarachchi; Konstanze Döhner; Sebastian Schwind; Kati Maharry; Benjamin Leffel; Hartmut Döhner; Michael D Radmacher; Clara D Bloomfield; Stephan M Tanner; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-09       Impact factor: 11.205

5.  Role of BAALC Gene in Prognosis of Acute Lymphoblastic Leukemia in Egyptian Children.

Authors:  Adel A Hagag; Walid A Elshehaby; Nahd M Hablas; Mohamed M Abdelmageed; Amal Ezzat Abd El-Lateef
Journal:  Indian J Hematol Blood Transfus       Date:  2017-06-23       Impact factor: 0.900

6.  Enhancing effect of β-elemene emulsion on chemotherapy with harringtonine, aclacinomycin, and Ara-c in treatment of refractory/relapsed acute myeloid leukemia.

Authors:  Cuiping Zheng; Xiaoping Cai; Shenghao Wu; Zhen Liu; Yuejian Shi; Wenjin Zhou
Journal:  Pak J Med Sci       Date:  2014 Nov-Dec       Impact factor: 1.088

7.  Prognostic value of brain and acute leukemia cytoplasmic gene expression in egyptian children with acute myeloid leukemia.

Authors:  Adel A Hagag; Amal Ezzat Abd El-Lateef
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-04-20       Impact factor: 2.576

8.  High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.

Authors:  Wen Du; Jing He; Wei Zhou; Simin Shu; Juan Li; Wei Liu; Yun Deng; Cong Lu; Shengyan Lin; Yaokun Ma; Yanli He; Jine Zheng; Jiang Zhu; Lijuan Bai; Xiaoqing Li; Junxia Yao; Dan Hu; Shengqing Gu; Huiyu Li; Anyuan Guo; Shiang Huang; Xiaolan Feng; Dong Hu
Journal:  J Transl Med       Date:  2019-06-06       Impact factor: 5.531

9.  A Novel Role for Brain and Acute Leukemia Cytoplasmic (BAALC) in Human Breast Cancer Metastasis.

Authors:  Madeleine Birgersson; Mengna Chi; Chrissy Miller; Joshua S Brzozowski; Jeffrey Brown; Lachlan Schofield; Olivia G Taylor; Elizabeth A Pearsall; Jasmine Hewitt; Craig Gedye; Lisa F Lincz; Kathryn A Skelding
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

10.  A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALC.

Authors:  Jaap Brand; Martin H van Vliet; Leonie de Best; Peter Jm Valk; Henk E Viëtor; Bob Löwenberg; Erik H van Beers
Journal:  Exp Hematol Oncol       Date:  2013-03-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.